Skip to main content
. Author manuscript; available in PMC: 2016 Apr 25.
Published in final edited form as: Breast Cancer Res Treat. 2013 Oct 25;142(1):45–57. doi: 10.1007/s10549-013-2733-5

Figure 2. Bryostatin 1 and Ionomycin are required for NKT cell activation.

Figure 2

The contribution of B/I to cellular activation of CD56+ and CD161+ NKT cells was determined using flow cytometry analysis to compare reprogrammed PBMCs, to those treated only with common γ-c cytokines ex vivo for six days (IL-2/7/15, n=3). Data represent Mean ± SEM